|
1
|
Goldstraw P, Ball D, Jett JR, Le Chevalier
T, Lim E, Nicholson AG and Shepherd FA: Non-small-cell lung cancer.
Lancet. 378:1727–1740. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
van Meerbeeck JP, Fennell DA and De
Ruysscher DK: Small-cell lung cancer. Lancet. 378:1741–1755. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
NCCN practice guidelines in
oncology-non-small cell lung cancer, V.2.2018. Available at.
https://www.nccn.org
|
|
4
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wakuda K, Kenmotsu H, Serizawa M, Koh Y,
Isaka M, Takahashi S, Ono A, Taira T, Naito T, Murakami H, et al:
Molecular profiling of small cell lung cancer in a Japanese cohort.
Lung Cancer. 84:139–144. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Canale M, Petracci E, Delmonte A, Chiadini
E, Dazzi C, Papi M, Capelli L, Casanova C, De Luigi N, Mariotti M,
et al: Impact of TP53 mutations on outcome in EGFR-mutated patients
treated with first-line tyrosine kinase inhibitors. Clin Cancer
Res. 23:2195–2202. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stewart EL, Tan SZ, Liu G and Tsao MS:
Known and putative mechanisms of resistance to EGFR targeted
therapies in NSCLC patients with EGFR mutations-a review. Transl
Lung Cancer Res. 4:67–81. 2015.PubMed/NCBI
|
|
9
|
Oser MG, Niederst MJ, Sequist LV and
Engelman JA: Transformation from non-small-cell lung cancer to
small-cell lung cancer: Molecular drivers and cells of origin.
Lancet Oncol. 16:e165–e172. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brierley JD, Gospodarowicz MK and
Wittekind C: TNM classification of malignant tumours (8th).
Wiley-Blackwell. January;2017.
|
|
11
|
NCCN Practice Guidelines in
Oncology-Non-small Cell Lung Cancer, V.2.2008. Available at.
https://www.nccn.org
|
|
12
|
Shu Y, Wu X, Tong X, Wang X, Chang Z, Mao
Y, Chen X, Sun J, Wang Z, Hong Z, et al: Circulating tumor DNA
mutation profiling by targeted next generation sequencing provides
guidance for personalized treatments in multiple cancer types. Sci
Rep. 7:5832017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Amarasinghe KC, Li J, Hunter SM, Ryland
GL, Cowin PA, Campbell IG and Halgamuge SK: Inferring copy number
and genotype in tumour exome data. BMC Genomics. 15:7322014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shepherd FA, Rodrigues Pereira J, Ciuleanu
T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S,
Smylie M, Martins R, et al: Erlotinib in previously treated
non-small-cell lung cancer. N Engl J Med. 353:123–132. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Peifer M, Fernández-Cuesta L, Sos ML,
George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander
T, et al: Integrative genome analyses identify key somatic driver
mutations of small-cell lung cancer. Nat Genet. 44:1104–1110. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Massarelli E, Varella-Garcia M, Tang X,
Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS and Wistuba II:
KRAS mutation is an important predictor of resistance to therapy
with epidermal growth factor receptor tyrosine kinase inhibitors in
non-small-cell lung cancer. Clin Cancer Res. 13:2890–2896. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bass AJ, Watanabe H, Mermel CH, Yu S,
Perner S, Verhaak RG, Kim SY, Wardwell L, Tamayo P, Gat-Viks I, et
al: SOX2 is an amplified lineage-survival oncogene in lung and
esophageal squamous cell carcinomas. Nat Genet. 41:1238–1242. 2009.
View Article : Google Scholar : PubMed/NCBI
|
